Product Pipelines

Hemogen, a subsidiary company of BGI Group, adheres to the vision of BGI - "Omics for All". Supported by the strong scientific research capabilities of BGI-Research and BGI Group's channel influence in the medical and health science field, Hemogen is committed to the treatment of hemoglobin diseases and to "Create A Thalassemia Free World Together".

  • Program
  • Indications
  • Early R&D
  • Preclinical
  • IIT
  • Phase I/II
  • Phase III
  • HGI-001
  • Transfusion-dependent beta-thalassemia
  • HGI-002
  • Transfusion-dependent alpha-thalassaemia
  • HGI-003
  • Rare disease
  • HGI-004
  • Rare disease
  • HGI-005
  • Rare disease
info@hemogen.cn